Free tool
FAERS Monitor: Rivfloza
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 215842 or its brand name (Rivfloza, Nedosiran Sodium). Reports on generic versions are filed under their own applications.
Reports
12
Serious
8
67% of reports
Hospitalization
3
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- urine oxalate increased3
- inappropriate schedule of product administration2
- rash2
- abdominal pain1
- amenorrhoea1
- bone pain1
- death1
- dehydration1
- diabetes mellitus1
- drug ineffective1
- febrile infection1
- haemoglobin increased1
- hyperoxalaemia1
- hyperoxaluria1
- influenza1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2024 | 3 |
| 2025 | 9 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,147 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hyperoxalaemia | 1 | 159501.1 | 22301.2 | 36,551 |
| urine oxalate increasedSignal | 3 | 75193.4 | 27452.4 | 150,211 |
| hyperoxaluria | 1 | 10260.3 | 1561.7 | 2,549 |
| febrile infection | 1 | 1491.9 | 228.2 | 372 |
| haemoglobin increased | 1 | 384.3 | 58.8 | 95 |
| amenorrhoea | 1 | 99.9 | 15.3 | 24 |
| bone pain | 1 | 29.9 | 4.6 | 7 |
| diabetes mellitus | 1 | 23.0 | 3.5 | 5 |
| inappropriate schedule of product administration | 2 | 19.5 | 5.5 | 19 |
| influenza | 1 | 15.7 | 2.4 | 3 |
| dehydration | 1 | 13.1 | 2.0 | 2 |
| rash | 2 | 8.0 | 2.3 | 6 |
| abdominal pain | 1 | 7.5 | 1.2 | 1 |
| death | 1 | 2.0 | 0.3 | 0 |
| drug ineffective | 1 | 1.3 | 0.2 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.